TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients

Composition of the intestinal microbiota has been correlated to therapeutic efficacy of immune check‑point inhibitors (ICI) in various cancer entities including melanoma. Prediction of the outcome of such therapy, how‑ever, is still unavailable.